IPHYF — Innate Pharma SA
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1598599 ·
France
Last close
$1.51
Market Cap
$168.56M
52W High
$2.25
52W Low
$1.37
ADV30
33
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 34,726,000 | 6,461,000 | 75,234,000 |
| Dec 2025 | — | — | — | — | 62,719,000 | 28,092,000 | 84,423,000 |
| Jun 2025 | — | — | — | — | 92,937,000 | 53,704,000 | 87,793,000 |
| Dec 2024 | — | — | — | — | 111,059,000 | 66,396,000 | 102,225,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-435,542,000
Inventory
—
Receivables
$7,610,000
ST Investments
$6,218,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,005,000
EBITDA
$-53,309,000
Free Cash Flow
$-34,073,624
Enterprise Value
$143,016,576
Total Cash
$34,310,000
Total Debt
$22,573,000
Shares Out
111,700,347
Trailing EPS
$-0.64
Book Value
$-0.27
ROE
—
ROA
-38.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,787,000 | -53,425,000 | -49,177,000 | 62,719,000 | 84,423,000 | -21,704,000 | -32,559,000 |
| Dec 2024 | 12,621,000 | -51,576,000 | -49,471,000 | 111,059,000 | 102,225,000 | 8,834,000 | -6,896,000 |
| Dec 2023 | 51,901,000 | -12,669,000 | -7,570,000 | 175,187,000 | 123,286,000 | 51,901,000 | -52,755,000 |
| Dec 2022 | 49,580,000 | -16,425,000 | -58,103,000 | 199,295,000 | 145,144,000 | 54,151,000 | -19,155,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IPHA | Innate Pharma SA | $165.32M | $1.48 | — |
| CHRS | Coherus Oncology, Inc. | $165.32M | $1.07 | — |
| CMPX | Compass Therapeutics, Inc. | $177.10M | $0.98 | — |
| DTIL | PRECISION BIOSCIENCES INC | $177.48M | $6.43 | — |
| TARA | Protara Therapeutics, Inc. | $156.60M | $2.65 | — |
News headlines (Yahoo Finance, 1h cache)
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
2026-10-08 12:35 · Yahoo
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
2026-10-05 12:35 · Yahoo
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
2026-09-23 16:00 · Yahoo
Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?
2026-09-23 00:40 · Yahoo
Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript
2026-09-18 03:07 · Yahoo
Innate Pharma Q2 Earnings Call Highlights
2026-09-17 13:02 · Yahoo
Innate Pharma Reports First Half 2026 Business Update and Financial Results
2026-09-17 05:00 · Yahoo
Sobi and Innate announce partnership is now effective following completion of closing conditions
2026-09-17 03:28 · Yahoo
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
2026-09-16 20:00 · Yahoo
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
2026-09-10 05:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.